Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first- line treatment for patients with metastatic colorectal cancer (FIRE -3): a randomised, open-label, phase 3 trial. Lancet Oncol.